Drug Pricing
RegulationWatch reporting on drug pricing matters involving US pharmaceutical manufacturers, PBMs and healthcare companies, newest first.
- 340B Program (1)
- Anti-Kickback Statute (3)
- Antitrust (6)
- Controlled Substances Act (3)
- Drug Pricing (8)
- Drug Promotion (1)
- FTC Enforcement (2)
- FTC Report (1)
- False Claims Act (9)
- Marketing Fraud (2)
- Medicare Advantage (1)
- Medicare Negotiation (1)
- Merger Conditions (1)
- Off-Label Promotion (1)
- Opioid Distribution (1)
- Opioid Litigation (4)
- PBM Oversight (1)
- PBM Rebates (7)
- Patent Litigation (1)
- State Enforcement (4)
- Drug Pricing
Pennsylvania sues the three largest insulin makers and PBMs over alleged pricing scheme
Pennsylvania Attorney General Dave Sunday sued Eli Lilly, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark and OptumRx under the state's consumer protection law. Because Pennsylvania has no general antitrust statute, the case relies on deception claims rather than price-fixing law.
- Drug Pricing
Public order discloses reversal of $48 million award against OptumRx
A Florida federal court publicly released an order vacating a $48,362,033 arbitration award against OptumRx entities. The underlying decision was dated September 17.
- Drug Pricing
CMS finalises international benchmark model for Medicare Part B drugs
CMS finalised the GLOBE drug-payment model, with initial reporting in January 2027 and its performance period beginning April 2027. The rule is a payment-policy measure, not an enforcement finding against manufacturers.
- Drug Pricing
Fruth reimbursement claims move to arbitration and Missouri federal court
A West Virginia federal judge ordered arbitration of Fruth's claims against OptumRx and Caremark. Claims against Express Scripts were severed and transferred to Missouri.
- Drug Pricing
Arkansas pharmacies sue Express Scripts over alleged reimbursement floor violations
Twelve Arkansas pharmacies filed a private lawsuit against Express Scripts in Missouri state court, alleging reimbursements below Arkansas's statutory minimum. They seek damages and court-ordered changes; the filing establishes no liability.
- Drug Pricing
Oregon seeks $900 million from insulin makers and PBMs over pricing
Oregon Attorney General Dan Rayfield has filed a $900 million lawsuit against Novo Nordisk, Sanofi, Eli Lilly, Express Scripts, CVS Caremark and Optum, alleging a coordinated scheme to inflate insulin and diabetes drug prices. The 173-page complaint was filed in Multnomah County Circuit Court.
- Drug Pricing
Eli Lilly settles with Minnesota to cap insulin at $35 a month for uninsured residents
Minnesota Attorney General Keith Ellison announced a settlement with Eli Lilly under which Lilly agreed to cap insulin prices at $35 per month for uninsured Minnesotans and donate insulin to free clinics serving low-income patients. No liability was admitted. The settlement built on Minnesota's 2020 Alec Smith Insulin Affordability Act.
- Drug Pricing
Federal judge rejects Merck's constitutional challenge to Medicare drug price negotiation
Judge Colleen Kollar-Kotelly of the US District Court for the District of Columbia rejected Merck's First and Fifth Amendment challenge to the Inflation Reduction Act's Medicare drug price negotiation programme. Merck filed the first industry challenge to the programme in June 2023.
